Corporate support helps the GI Cancer Institute unlock the answers to better treatments for the 28,600 Australians diagnosed with gastro-intestinal (GI) cancer each year.
With 39 Australians losing their battle to the disease every day, the stakes are high.
The GI Cancer Institute aims to raise money for GI cancer clinical trials research conducted by the Australasian Gastro-Intestinal Trials Group (AGITG). The AGITG is comprised of over 1,000 medical professionals who volunteer their time. AGITG research is conducted independently of the corporate supporters of the GI Cancer Institute.
We thank the following companies for their recent support.
Corporate Sponsors – Platinum
Servier possesses a unique cultural heritage as an international, independent, French research-based ethical pharmaceutical Company governed by a non-profit foundation. Servier produces innovative drugs for doctors and their patients around the world. At the same time, driven by the medical needs of humankind and advances in science and technology, Servier strives to meet the demands of the future.
Additional information can be found at www.servier.com.au.
Corporate Sponsors – Gold
AstraZeneca is a global, science-led biopharmaceutical company that focuses
on the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas – Respiratory &
Autoimmunity, Cardiovascular & Metabolic Disease and Oncology.
The Company is also active in inflammation, infection and neuroscience through
numerous collaborations. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.